AI in Healthcare

Is AI accelerating or delaying the path to new treatments? A $150M Series D funding round for an AI drug discovery platform underscores investor confidence in transforming pharmaceutical innovation. But what does this mean for global health outcomes and clinical trial efficiency? This trend signals a major shift in how drugs are discovered, with AI tools poised to reshape R&D from the ground up. Source: BioPharma Dive · Published September 01, 2026 View and join any or all of our communities — AI, quantum, and real estate: https://alex-companies.com/reports/linkedin-groups If there's an AI, quantum, or real estate community you'd like to see us convene, tell us — this portfolio grows by request. MIT, Nvidia, Google & IBM-Trained. Cross Domain-Expert: Quantum, AI, Ethics, Sovereignty, Intelligence, Philanthropy. Solepoint Planning. VUI AI Cloud Architect. AI Certifications Development. Quant/AI Instructor. Castor Venture Club Member. Associate Broker. George Arnold Alexander III Director, ALEX Companies; Associate Broker, Alexander Tiffany Southwest, LLC. +1 713.918.9951 · [email protected]